re: #233 opnion

But it is not unusual to grant multiple extensions. I have no problem at all with the R&D company7 recouping it’s investment & realising a good profit.
My problem is when their patent goes on & on & they set an uneasonable price

I’m not sure what the requirements are for obtaining extensions. They may - or may not - be acceptable.

Without a doubt, the drug approval process in the US needs an overhaul, both in terms of streamlining and in terms of excluding authorities from the approval process who are also directly involved with the success of a given product.